From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Neurotherapeutics Network Product Development RFI

by Global Biodefense Staff
March 22, 2013

The Blueprint Neurotherapeutics Network (BPN) through the National Institute of Neurological Disorders and Stroke (NINDS) is considering developing a drug product development program for the manufacture and formulation of dosage forms suitable for administration in preclinical and clinical studies.

The goal of the product development program is to manufacture the active pharmaceutical ingredient (API), formulate the API, package, label, store, and distribute completed drug product to preclinical and clinical trial sites. The NINDS envisions awarding a contract for drug manufacturing and formulation services. The Institute is conducting market research to help determine how best to structure contracts for this work.

The BPN offers neuroscience researchers a “virtual pharma” network of contract service providers and consultants with extensive industry experience to develop promising hit compounds from chemical optimization through Phase I human clinical testing. A long term goal is to produce effective medication for a disorder of the nervous system that is currently poorly treated or untreatable. BPN will provide early chemistry knowledge and assist in technology transfer from discovery labs to the product development service provider. Services described below are important next steps for BPN contributors and quality service facilities are needed to develop and prepare drug products for human testing.

The NINDS is considering a drug product development program to assist our BPN contributors. This program is envisioned as a collaborative effort between a service facility and contributors with compounds ready to manufacture.

The service facility shall provide:

  • • Chemistry scale up and process development
  • • Manufacture of active pharmaceutical ingredients
  • • Receipt and storage of API
  • • Preformulation & Formulation of API
  • • Fill and finish of formulations suitable for clinical trial
  • • Packaging, labeling, and storage
  • • Distribution to clinical trial sites

This Request for Information (RFI) seeks input on the design of this program from potential service contractors with staffing and equipment for drug product development studies and GMP manufacturing through Phase I and/or Phase II clinical trials.

Further details are available under Solicitation Number: NINDS-RFI-NS-13-001. Responses are due by April 22, 2013.

Read more about the network: NIH Blueprint for Neuroscience Research.

From Our Partners
Tags: RFI

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC